Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.82 USD | +1.45% | +16.26% | -8.65% |
May. 10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.65% | 1.41B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation